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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of commonly fatal malignancies of immunocompro-
mised individuals, including primary effusion lymphoma (PEL) and Kaposi’s sarcoma (KS). A hallmark of all herpesviruses is
their biphasic life cycle—viral latency and the productive lytic cycle—and it is well established that reactivation of the KSHV
lytic cycle is associated with KS pathogenesis. Therefore, a thorough appreciation of the mechanisms that govern reactivation is
required to better understand disease progression. The viral protein replication and transcription activator (RTA) is the KSHV
lytic switch protein due to its ability to drive the expression of various lytic genes, leading to reactivation of the entire lytic cycle.
While the mechanisms for activating lytic gene expression have received much attention, how RTA impacts cellular function is
less well understood. To address this, we developed a cell line with doxycycline-inducible RTA expression and applied stable iso-
tope labeling of amino acids in cell culture (SILAC)-based quantitative proteomics. Using this methodology, we have identified a
novel cellular protein (AT-rich interacting domain containing 3B [ARID3B]) whose expression was enhanced by RTA and that
relocalized to replication compartments upon lytic reactivation. We also show that small interfering RNA (siRNA) knockdown
or overexpression of ARID3B led to an enhancement or inhibition of lytic reactivation, respectively. Furthermore, DNA affinity
and chromatin immunoprecipitation assays demonstrated that ARID3B specifically interacts with A/T-rich elements in the
KSHV origin of lytic replication (oriLyt), and this was dependent on lytic cycle reactivation. Therefore, we have identified a novel
cellular protein whose expression is enhanced by KSHV RTA with the ability to inhibit KSHV reactivation.
IMPORTANCE
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of fatal malignancies of immunocompromised individu-
als, including Kaposi’s sarcoma (KS). Herpesviruses are able to establish a latent infection, in which they escape immune detec-
tion by restricting viral gene expression. Importantly, however, reactivation of productive viral replication (the lytic cycle) is
necessary for the pathogenesis of KS. Therefore, it is important that we comprehensively understand the mechanisms that gov-
ern lytic reactivation, to better understand disease progression. In this study, we have identified a novel cellular protein (AT-rich
interacting domain protein 3B [ARID3B]) that we show is able to temper lytic reactivation. We showed that the master lytic
switch protein, RTA, enhanced ARID3B levels, which then interacted with viral DNA in a lytic cycle-dependent manner. There-
fore, we have added a new factor to the list of cellular proteins that regulate the KSHV lytic cycle, which has implications for our
understanding of KSHV biology.
Infection of immunocompromised people with Kaposi’s sarco-ma-associated herpesvirus (KSHV) is frequently linked with fa-
tal malignancies. It is well established as the causative agent of
primary effusion lymphoma (PEL) and Kaposi’s sarcoma (KS)
and is often associated with multicentric Castleman’s disease
(MCD) (1, 2). As with all herpesviruses, KSHV infection is lifelong
and has two distinct phases to its life cycle: latency and the lytic
cycle. Latency is associated with a highly restrictive viral gene ex-
pression program involving the latency-associated nuclear anti-
gen (LANA), viral FLICE inhibitory protein (vFLIP), viral cyclin,
kaposin, and various virally encoded microRNAs (miRNAs), and
together, these are required for maintenance of the KSHV genome
in vitro (3) and tumorigenesis in vivo (2). However, reactivation
from latency to the lytic cycle is indispensable for the pathogenesis
of KS; indeed, active virus replication and increased viral loads are
associated with poorer clinical outcomes (4–6), and there is clin-
ical evidence that treatment of patients with ganciclovir (inhibitor
of herpesvirus replication) significantly reduces the incidence of
KS (7). Therefore, a comprehensive understanding of molecular
mechanisms that govern KSHV reactivation is critical to our un-
derstanding of disease progression.
Expression of a single viral protein, replication and transcrip-
tional activator (RTA), is both necessary and sufficient for reacti-
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vation of the KSHV lytic cycle (reviewed in reference 8). In vitro,
RTA expression is stimulated by certain cellular cues such as
plasma cell differentiation (9, 10) and hypoxia (11), and because
RTA autoactivates its own promoter and drives the full lytic cycle,
it is well established as the true KSHV lytic switch protein (8). RTA
activates transcription of lytic genes by directly interacting with
RTA-responsive elements (RREs) found in some lytic gene pro-
moters, or indirectly via interactions with cellular transcription
factors, particularly RBP-J, AP-1, and Oct-1 (8). The RTA pro-
tein comprises all the elements that one would expect for a tran-
scriptional activator, such as nuclear localization signals (NLSs), a
DNA binding domain (DBD), and a transcriptional activation
(TA) domain. Further functional domains have also been identi-
fied, such as a leucine zipper domain that is important for homo-
tetramer formation (12), a serine/threonine-rich region that is
subject to phosphorylation (13), and a multitude of binding sites
for various protein-protein interactions (PPIs) (8).
The best-characterized lytic promoters that are dependent on
the direct DNA binding mechanism are the PAN and K12 pro-
moters (14, 15). Both genes are highly expressed during lytic re-
activation, but their expression is prevented when DNA binding
mutants of RTA are expressed (15). Furthermore, transfection
experiments with plasmids containing the PAN promoter showed
that RTA was essential for activating transcription, as mRNA was
undetectable in its absence (16). The sequence elements that were
found to be RTA responsive demonstrated significant homology
between the PAN and K12 promoters and centered on an A/T-rich
trinucleotide (17) reminiscent of interferon-stimulated response
elements found in the promoters of interferon-dependent genes
(18).
There are several lytic genes that are activated via the indirect
mechanism, including the RTA gene itself (ORF50), ORF57
(Mta), ORF6, ORF74 (vGCPR), K6 (vMIP-1), and ORF73 (LANA)
(15, 19, 20). However, whether RTA’s intrinsic DNA binding
property is important for the activation of promoters via the in-
direct mechanism is a contentious issue. While some believe that
RTA’s ability to transactivate the ORF57 promoter is completely
dependent on PPIs (15), others suggest that cooperation between
RTA-DNA interactions and PPIs enhances the activation of tran-
scription. For example, in addition to the essential RBP-J bind-
ing site found in the ORF57 promoter, RTA binding sites have
been identified surrounding this region and have been character-
ized as partial palindromes of A/T-rich elements with a 5=-
CANT-3= (N  any nucleotide) repeat core element (21). Exten-
sive analysis of this promoter element suggested a model whereby
RTA recruits RBP-J to its consensus binding sequence, and
through tetramer formation, RTA makes contacts with its cognate
CANT repeats (21). Furthermore, stabilization of this complex
may occur via further upstream CANT repeat interactions involv-
ing additional cellular transcription factors, such as AP-1 (8).
RTA is also required to coordinate lytic replication of the
KSHV genome at the cis-acting origins of lytic replication (oriLyt).
For example, it is responsible for docking the viral prereplication
complex at the oriLyt (22), and this process, for unknown reasons,
requires RTA-mediated transcription of an oriLyt-associated
transcript (23, 24). Two distinct oriLyt sequences have been iden-
tified in the KSHV genome (oriLyt left and right); interestingly,
RREs in oriLyt left share significant homology to those found in
the PAN and K12 promoters (23). Furthermore, oriLyt contains
an A/T-rich region consisting of various palindromic sequences in
addition to a highly G/C-rich repeat element. Interestingly, DNA
affinity studies have demonstrated that several cellular proteins
preferentially interact with oriLyt via its A/T-rich regions (25).
Unlike most other herpesviruses, de novo infection of cell lines
with KSHV leads to latency where the viral genome is rapidly
chromatinized and lytic genes are associated with repressive his-
tone modifications (26–28), making KSHV an amenable model
for studying the establishment of herpesvirus latency. Further-
more, reactivation of the lytic cycle promotes various negative-
feedback mechanisms that serve to temper lytic gene expression
during reactivation, and in vivo, these presumably function to
promote the establishment or maintenance of latency. These in-
clude viral factors (e.g., LANA [29, 30] and viral miRNAs [31])
and cellular proteins [e.g., NF-B (32), TLE2 (33), poly(ADP-
ribose) polymerase (PARP-1) (34), and histone deacetylase 1
(HDAC1) (35)] which have been found to temper RTA transacti-
vation of its target promoters and thus reactivation of the lytic
cycle. Clearly, silencing of KSHV lytic gene expression, or inhibi-
tion of lytic DNA replication, is an important step in the life cycle
of KSHV. Nevertheless, the mechanisms that are involved are
poorly understood.
To begin to gain an understanding of how RTA expression
impacts the cellular proteome, we employed a global quantitative
proteomics approach using stable isotope labeling of amino acids
in cell culture coupled to tandem mass spectrometry (SILAC-MS/
MS). Quantitative proteomics, using various platforms, is a pow-
erful method that has been employed by various laboratories, in-
cluding our own (36–38), to investigate virus-host interactions
(recently reviewed in references 39 and 40). Using this approach,
we identified a novel protein, A/T-rich interacting domain 3B
(ARID3B), whose expression was enhanced by RTA and that reg-
ulated the KSHV lytic cycle. ARID3B, so called as it contains an
A/T-rich interactive domain (ARID), belongs to a family of pro-
teins involved in the regulation of gene expression. The ARID of
ARID3A (a paralogue of ARID3B that functions as a B cell activa-
tor) has been shown to preferentially bind AATTAA sequences
(41, 42); as this domain shares 89.9% sequence identity with that
found in ARID3B, it suggests that there is functional conservation
between these proteins.
As a transcription factor (43, 44), ARID3B promotes survival
during development (44–46), and it is these properties that link it
with various malignancies (43, 47–52). Very little else is known
about ARID3B; however, we reasoned that its prosurvival proper-
ties may be important during the KSHV lytic cycle and it might
promote lytic gene expression, thus explaining its RTA-mediated
enhanced expression. However, we found that ARID3B inhibited
lytic reactivation, and as it preferentially bound to regions con-
taining A/T-rich elements in oriLyt, we consider the possibility
that either it prevents oriLyt-dependent gene expression or it
blocks access to proteins essential for viral genome replication.
MATERIALS AND METHODS
Cell lines, plasmids, and transfections. TREx-BCBL-1-RTA cells (a kind
gift from Jae Jung, University of Southern California) are a BCBL-1-based
cell line that has been engineered to inducibly express exogenous Myc-
tagged RTA by the addition of 1 g/ml doxycycline hyclate, leading to a
robust reactivation of the full KSHV lytic cycle (53); these were cultured in
RPMI 1640 (Lonza) supplemented with 10% fetal bovine serum (FBS)
(Life Technologies). Inducible SLK-BAC16 cells (iSLK-BAC16; also a gift
from Jae Jung) were grown in Dulbecco modified Eagle medium
(DMEM) (Lonza) supplemented with 10% FBS (Life Technologies).
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These maintain a latent infection with bacterial artificial chromosome 16
(BAC16)-derived KSHV (54). The parental SLK cell line, originally con-
sidered KSHV-negative endothelial cells derived from a KS patient, was
subsequently found to be a contaminant of a renal carcinoma cell line,
Caki1 (55). Nevertheless, these cells are widely used as a model for the
study of KSHV biology. Initially, these cells were engineered to inducibly
express RTA (iSLK) following the addition of doxycycline (56) and sub-
sequently transfected with BAC16 and selected based on BAC-derived
puromycin resistance (54). This cell line was demonstrated to support an
authentic latent infection, and induction of the lytic cycle (with 1 g/ml
doxycycline hyclate) leads to the release of infectious virus (54).
HEK293T cells were used for reinfection assays as previously described
(57). HEK293 rKSHV.219 cells (58) maintain KSHV as a latent infection
and were generated by infecting HEK293T cells with a recombinant
KSHV that contains a constitutively active puromycin resistance and
green fluorescent protein (GFP) gene and a red fluorescent protein (RFP)
gene that is fused to an RTA-responsive lytic cycle (PAN) promoter (not
utilized in this study). Both HEK293T-based cell lines were maintained in
DMEM (Lonza) supplemented with 10% FBS (Life Technologies).
To generate cells with inducible N-terminal FLAG-His-tagged RTA
expression (iRTA-293), RTA was amplified from pRTS-ORF50 (14) (for-
ward primer, 5=-ATCTTAAGGCCACCATGGATTATAAAGATGACGA
TGACAAGCATCATCATCATCATCATGCGCAAGATGACAAGGGTA
AG-3=; reverse primer, 5=-ATCTCGAGTCAGTCTCGGAAGTAATTAC
G-3=) and ligated into the AflI-XhoI sites of pcDNA5-FRT-TO (Life Tech-
nologies) to generate pcDNA5-FH-RTA. Functionality of this vector was
demonstrated due to its ability to reactivate the KSHV lytic cycle following
its transfection. Flp-In-293 cells (Life Technologies) were transfected
along with pOG44 (Flp recombinase) and subsequently selected using
hygromycin B according to the manufacturer’s protocol (Life Technolo-
gies). Clonal populations were generated by limiting dilution under hy-
gromycin B selection, and clones with tightly regulated expression and
normal growth properties (compared to parental cells) were selected.
RTA expression was induced following treatment with 1 g/ml doxycy-
cline hyclate for the indicated times. iRTA-293 cells were maintained in
DMEM (Lonza) supplemented with 10% FBS (Life Technologies).
The vector expressing C-terminally FLAG-tagged ARID3B was gener-
ated by PCR amplification using an ARID3B-containing plasmid (kind
gift from Karen Cowden Dahl, Indiana University) as the template
(forward primer, 5=-CGCGGATCCAAGCGATGGAGCCACTTCAGC
AGCAGCAGCA-3=; reverse primer, 5=-CGCGAATTCTCACTTATCG
TCGTCATCCTTGTAATCGAGGGACCAGCTGGTGGAGGGCTC-
3=). Products were digested and ligated into the BamHI and EcoRI sites
of pcDNA3 (pcDNA3-ARID3B-FLAG). FLAG-tagged SRAG was a
kind gift from Stuart Wilson (University of Sheffield). Expression con-
structs were verified by DNA sequencing.
For transfections, cells were plated into 6-well plates, and transfections
routinely used 1 g plasmid DNA and Lipofectamine 2000 (Life Technol-
ogies) according to the manufacturer’s instructions.
To determine the effects of overexpressed proteins on virus reactiva-
tion efficiencies, iSLK-BAC16 cells were transfected for 24 h and the lytic
cycle was induced by doxycycline treatment for a further 24 h. Samples
were processed for immunoblot analysis (see below).
Stable isotope labeling of amino acids in cell culture (SILAC) pro-
teomics. iRTA-293 cells were grown in “heavy”-labeled medium contain-
ing stable isotopes of arginine (R) and lysine (K) (R10K8; DMEM-16;
Dundee Cell Products) or “light”-labeled medium (R0K0; DMEM-14;
Dundee Cell Products) supplemented with 10% dialyzed fetal calf serum
(FCS) (DS1003; Dundee Cell Products) for 2 weeks. Cells were grown to
80 to 90% confluence in 10-cm dishes that included poly-L-lysine-coated
coverslips, used to verify RTA expression by immunofluorescence (see
below). RTA expression was induced for 12 h following treatment of
heavy-labeled cells with 1 g/ml doxycycline hyclate. To reduce sample
complexity and to investigate how RTA expression impacts the nuclear
proteome, labeled cells were fractionated (verified by immunoblotting;
see below). After the monolayer was rinsed with phosphate-buffered sa-
line (PBS), 1  107 cells from each culture were lysed in 5 ml cytoplasmic
lysis buffer containing 20 mM Tris (pH 7.4), 100 mM NaCl, 0.5 mM
EDTA, 0.5% NP-40, and 1 protease inhibitor cocktail (Roche) for 20
min at 4°C. The nuclei were pelleted at 2,000  g for 5 min at 4°C, and the
cytoplasmic fraction was removed and stored. Nuclei were washed three
times in cytoplasmic lysis buffer, and then nuclear proteins were extracted
using 200 l radioimmunoprecipitation assay (RIPA) buffer by repeated
pipetting and storage on ice for 15 min. Insoluble material was pelleted at
12,000  g for 10 min, and the supernatant was removed.
Equal amounts of protein from unlabeled and labeled samples were
combined prior to protein digestion. Briefly, samples were reduced in 50
mM dithiothreitol (DTT)-1 NuPage LDS loading buffer and then sep-
arated by one-dimensional SDS-PAGE (4 to 12% Bis-Tris Novex minigel;
Life Technologies) and visualized by colloidal Coomassie blue staining
(Novex; Life Technologies). The entire protein gel lanes were excised and
cut into 10 slices each. Every gel slice was subjected to in-gel digestion with
trypsin overnight at 37°C. The resulting tryptic peptides were extracted by
formic acid (1%) and acetonitrile, lyophilized in a Speed Vac, and resus-
pended in 1% formic acid. Trypsin-digested peptides were separated us-
ing an Ultimate 3000 RSLC (Thermo Scientific) nanoflow liquid chroma-
tography (LC) system. On average, 0.5 g was loaded with a constant flow
of 5 l/min onto an Acclaim PepMap100 nanoViper C18 trap column
(100-m inner diameter, 2 cm; Thermo Scientific). After trap enrich-
ment, peptides were eluted onto an Acclaim PepMap RSLC nanoViper
C18 column (75 m, 15 cm; Thermo Scientific) with a linear gradient of 2
to 40% solvent B (80% acetonitrile with 0.08% formic acid) over 65 min
with a constant flow of 300 nl/min. The high-performance liquid chro-
matography (HPLC) system was coupled to a linear ion trap Orbitrap
hybrid mass spectrometer (LTQ Orbitrap Velos; Thermo Scientific) via a
nanoelectrospray ion source (Thermo Scientific). The spray voltage was
set to 1.2 kV, and the temperature of the heated capillary was set to 250°C.
Full-scan MS survey spectra (m/z 335 to 1,800) in profile mode were
acquired in the Orbitrap with a resolution of 60,000 after accumulation of
1,000,000 ions. The 15 most intense peptide ions from the preview scan in
the Orbitrap were fragmented by collision-induced dissociation (normal-
ized collision energy, 35%; activation Q, 0.250; activation time, 10 ms) in
the LTQ after the accumulation of 10,000 ions. Maximal filling times were
1,000 ms for the full scans and 150 ms for the MS/MS scans. Precursor ion
charge state screening was enabled, and all unassigned charge states as well
as singly charged species were rejected. The lock mass option was enabled
for survey scans to improve mass accuracy. Data were acquired using the
Xcalibur software. The raw mass spectrometric data files obtained for each
experiment were collated into a single quantitated data set using Max-
Quant (version 1.2.2.5) and the Andromeda search engine software. En-
zyme specificity was set to that of trypsin, allowing for cleavage N terminal
to proline residues and between aspartic acid and proline residues. Other
parameters used were (i) variable modifications, methionine oxidation,
protein N-acetylation, and Gln to pyro-Glu; (ii) fixed modifications, cys-
teine carbamidomethylation; (iii) database, target-decoy human Max-
Quant (ipi.HUMAN.v3.68); (iv) heavy labels, R10K8; (v) MS/MS toler-
ance, Fourier transform mass spectroscopy (FTMS), 10 ppm; ion trap
mass spectroscopy (ITMS), 0.6 Da; (vi) maximum peptide length, 6; (vii)
maximum missed cleavages, 2; (viii) maximum of labeled amino acids, 3;
and (ix) false discovery rate (FDR), 1%. Peptide ratios were calculated for
each arginine- and/or lysine-containing peptide as the peak area of labeled
arginine/lysine divided by the peak area of nonlabeled arginine/lysine for
each single-scan mass spectrum. Peptide ratios for all arginine- and lysine-
containing peptides sequenced for each protein were averaged. Data were
normalized using 1/median ratio value for each identified protein group
per labeled sample. Pathway analysis was performed using DAVID Bioin-
formatics Resources (https://david.ncifcrf.gov/) (59, 60) using proteins
that were at least 2-fold different.
Immunoprecipitation and immunoblotting. Immunoprecipitation
assays have been described previously (61). For immunoblot analysis, cells
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were washed in PBS and proteins were extracted in lysis buffer containing
50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, and 1 protease inhib-
itor cocktail (Roche) for 15 min on ice and clarified by centrifugation at
12,000  g for 10 min, 4°C. For the detection of ARID3B by immunoblot-
ting, we found that sonication prior to loading improved detection. SDS-
PAGE and immunoblotting of normalized protein concentrations fol-
lowed standard techniques using the following antibodies: rabbit
polyclonal antibody (PAb) anti-FLAG tag (1:1,000; Sigma), mouse mono-
clonal antibody (MAb) anti-ORF57 207.6 (1:1,000; Santa Cruz), RTA,
rabbit antiserum (1:400; gift from David Blackbourn, University of Sur-
rey), mouse MAb anti-glyceraldehyde-3-phosphate dehydrogenase (anti-
GAPDH) (1:5,000; Sigma), mouse MAb anti-lamin B1 (1:1,000; Santa
Cruz), rabbit anti-ARID3B (1:200; Abcam), anti-ORF59 (Autogen Bio-
clear), and sheep anti-KSHV minor capsid protein (mCP; 1:1,000; Exal-
pha Biologicals, Inc.). Proteins were detected by chemiluminescence (us-
ing horseradish peroxidase [HRP]-conjugated secondary antibodies),
and signals were captured digitally using the ChemiDoc MP Imager (Bio-
Rad), which ensures that signal saturation does not occur. ImageLab soft-
ware version 4.1 (Bio-Rad) was used to select and determine the back-
ground-subtracted density of the bands in all blots, and these were
normalized against expression of GAPDH.
Indirect immunofluorescence microscopy. As previously described
(62), coverslips were coated with poly-L-lysine and TREx-BCBL-1-RTA
cells were plated (1  106 per well of a 12-well plate) and doxycycline
hyclate treated (1 g/ml) for 18 h at 37°C. Following doxycycline hyclate
treatment of SILAC-labeled iRTA-293 cells (see above), coverslips were
removed from the 10-cm dishes and placed in a humidity chamber. Cells
were gently washed with PBS, fixed using 4% formaldehyde (in PBS) for
10 min, permeabilized with PBS–1% Triton X-100 for 10 min, and washed
three times with PBS as previously reported (62). Primary antibodies were
diluted in PBS-2% bovine serum albumin (BSA), added to cells, and in-
cubated in humidity chambers for 2 h at 37°C or overnight at 4°C followed
by 5 washes with PBS. The appropriate secondary antibodies (Alexa Fluor
488 or 594; Life Technologies) were diluted 1:500 in PBS-2% BSA and
incubated with cells for 1 h at 37°C followed by 5 washes with PBS. Cov-
erslips were mounted in Vectashield with 4=,6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories).
Incorporation of ethyldeoxyuridine (EdU) was performed using a
Click-iT EdU imaging kit (Life Technologies) (62). Briefly, 1  106 TREx-
BCBL-1-RTA cells were treated with doxycycline and the cells were plated
onto poly-L-lysine-coated coverslips. After 16 h, cells were pulsed for 45
min with 10 M EdU, washed, fixed, and permeabilized according to the
manufacturer’s recommendations. After detection of EdU (according to
the manufacturer’s protocol), the cells were washed and further incubated
with the indicated antibody for 1 h at 37°C, washed again, and incubated
with Alexa Fluor 488 goat anti-rabbit antibody (Life Technologies; 1:500
in PBS-2% BSA) for 1 h at 37°C. Finally, DNA was stained using Hoechst
33342 (1:20,00 in PBS) and mounted in Vectashield (Vector Laborato-
ries). Images were captured using an LSM510 or LSM700 laser scanning
microscope (Carl Zeiss) and processed using Zen imaging software (Carl
Zeiss).
Antibodies included rabbit anti-FLAG (1:250; Sigma), mouse anti-
Myc tag 9E10 (1:250; Sigma), RTA rabbit antiserum (1:100), and rabbit
anti-ARID3B (1:100; Abcam).
Quantitative PCR. For reverse transcriptase-quantitative PCR (RT-
qPCR), total cellular RNA was extracted from cells using TRIzol (Life
Technologies) according to the manufacturer’s instructions and contam-
inating DNA was removed using the DNA-free kit (Ambion). cDNA was
generated from 1 g RNA in 20-l reaction volumes using Moloney mu-
rine leukemia virus (M-MuLV) reverse transcriptase (RT; New England
BioLabs) according to the manufacturer’s recommendations with 5 ng
oligo(dT). In parallel, negative-control reactions were performed for each
RNA by omitting RT in order to confirm that quantification represented
cDNA and not contaminating DNA. For quantification of viral DNA, 1 
106 cells were treated with doxycycline hyclate or left untreated. At 72 h
postreactivation, total DNA was extracted using a DNA minikit (Qiagen)
and quantified by UV spectrophotometry. Viral DNA was quantified us-
ing primers specific for the ORF57 gene. Quantitative PCR mixtures (20
l) included 1 SensiMix SYBR green master mix (Bioline), 0.5 M
(each) primer, and 1 l cDNA or 3.4 ng total DNA. Cycling was per-
formed in a RotorGene Q machine (Eppendorf) and included an initial
10-min denaturation step at 94°C, followed by 40 cycles of 30 s at 94°C, 30
s at 60°C, and 30 s at 72°C. Melting curve analysis was performed between
65 and 95°C (with 0.2°C increments) to verify amplicon specificity. Quan-
tification of GAPDH mRNA (qRT-PCR) or GAPDH DNA (virus reacti-
vation) was used to normalize between samples, and the average cycle
threshold (CT) was determined from three independent samples from
independent cultures. Calculations were made using the CT method.
RNA interference (RNAi). Conditions for small interfering RNA
(siRNA) knockdown of ARID3B followed previously reported protocols
(57). Briefly, 20 nM SMARTpool:On-TARGETplus ARID3B siRNA (L-
012219-00-0005; Dharmacon), Hs_ARID3B_3 FlexiTube GeneSolution
(GS10620; Qiagen), or scramble control siRNA (siRNA controls from the
respective manufacturer were used as controls) was transfected into iSLK-
BAC16 cells for 72 h. For experiments that required reactivation of the
lytic cycle, doxycycline was added to cells for 24 h, as stated above.
In vitro DNA affinity assay. Assays were performed according to the
method in reference 25, with minor modifications: HEK293 rKSHV.219
cells in 6-well plates were transfected with pcDNA3-ARID3B-FLAG, and
the lytic cycle was induced for 24 h. oriLyt sequences 3F, 9F, and 11F were
amplified from the KSHV genome using 5=-biotinylated primers (primer
sequences already described [25]) and a control region of the KSHV ge-
nome (RTA gene body; forward primer, 5=-GTCTACCTTCCGAGGATT
ATGG-3=; reverse primer, 5=-GATTCTGGCATGAGACCGCTTC-3=).
PCR products were incubated with Dynabeads M-280 –streptavidin ac-
cording to the manufacturer’s recommendations (Life Technologies). Af-
finity purification followed the previously described methods (25).
ChIP. Cells were cross-linked with 1% formaldehyde (Thermo Scien-
tific; catalog no. 28908) for 10 min at room temperature. Glycine was
added to a final concentration of 125 mM to stop the cross-linking reac-
tion, and the samples were incubated for another 5 min at room temper-
ature. Cells were washed twice with ice-cold PBS and lysed in FastChIP
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5 mM
DTT, 0.5% IGEPAL CA-630, 1.0% Triton X-100) containing protease
inhibitors (Roche) as described previously (63, 64). Isolated nuclei were
resuspended in SDS lysis buffer (50 mM Tris-HCl [pH 8.1], 10 mM
EDTA, 1% SDS), and the samples were incubated on ice for 15 min.
Nuclear lysates were sonicated for 10 min in a Diagenode Bioruptor
Pico (30-s on-off intervals) and cleared by centrifugation for 30 min at
20,000  g and 4°C. Sheared chromatin from 9  106 cells (180 l) was
combined with 9 volumes of chromatin immunoprecipitation (ChIP) di-
lution buffer (16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, 1.2 mM EDTA,
1.1% Triton X-100, 0.01% SDS) and subjected to immunoprecipitation
for 16 h at 4°C with gentle rotation using 13 l of rabbit anti-ARID3B
antibody (Bethyl Laboratories; catalog no. A302-564A-M) or 4 g of nor-
mal rabbit IgG. Samples were centrifuged for 10 min at 20,000  g, 4°C, to
remove any precipitated material, and the supernatants were combined
with 20 l Magna ChIP protein A magnetic beads (Millipore; catalog no.
16-661) and incubated for 2 h at 4°C with gentle rotation. Immune com-
plexes were washed with 1 ml each of low-salt buffer (20 mM Tris-HCl
[pH 8.1], 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS),
high-salt buffer (20 mM Tris [pH 8.1], 0.5 M NaCl, 2 mM EDTA, 1%
Triton X-100, 0.1% SDS), and lithium chloride (LiCl) buffer (10 mM Tris
[pH 8.1], 0.25 M LiCl, 1 mM EDTA, 1% IGEPAL CA-630, 1% deoxycholic
acid), and twice with TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) buffer.
Elution of the chromatin-antibody complexes was carried out by incuba-
tion with 150 l freshly prepared elution buffer (100 mM NaHCO3, 1%
SDS) containing 1.5 l proteinase K (Roche; catalog no. 03 115 887 001)
at 62°C for 2 h, followed by a 10-min incubation step at 95°C. DNA was
purified using the NucleoSpin gel and PCR cleanup kit from Macherey-
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Nagel (catalog no. 740609) according to their DNA cleanup protocol for
samples containing SDS. DNA was eluted with 90 l buffer NE, and 5 l
of the DNA solution was used as the template DNA for qPCR using prim-
ers specific for the A/T-rich region of oriLyt left (forward primer, 5=-CC
CTCCTTTGTTTTCCGGAAG-3=; reverse primer, 5=CTCATCGGGCCC
TATTATAAAG-3=) and the RTA coding region (forward primer, 5=-GT
CTACCTTCCGAGGATTATGG-3=; reverse primer, 5=-GATTCTGGCA
TGAGACCGCTTC-3=).
RESULTS
ARID3B expression is enhanced by RTA. To investigate the im-
pact of the lytic switch protein RTA expression on the host pro-
teome, we developed a cell line with doxycycline-inducible RTA
expression (iRTA-293) and applied global proteomics using stable
isotope labeling of amino acids in cell culture (SILAC). After met-
abolically labeling cells in media containing different stable iso-
topes of arginine (R) and lysine (K) (e.g., R10K8 [heavy] or R0K0
[light]) for 2 weeks, we induced RTA expression from heavy-la-
beled cells for 12 h while leaving light-labeled cells untreated. We
tested RTA expression by immunofluorescence and then fraction-
ated cells into cytoplasmic and nuclear fractions that were vali-
dated by immunoblot analysis using cytoplasmic and nuclear
markers (Fig. 1A and B). Both these assays demonstrated the ex-
pected nuclear expression of RTA. We combined the nuclear frac-
tions (heavy versus light) 1:1 and applied LC-MS/MS (Dundee
Cell Products [see Materials and Methods]). Identified and quan-
tified proteins with a minimum of two unique peptides and a
change in abundance of 2-fold were taken forward for bioinfor-
matics analyses. KEGG pathway analysis of the nuclear proteome
of proteins increased in abundance upon RTA expression (using
DAVID Bioinformatics Resources [59, 60]) identified various
pathways that one might expect to be modulated upon RTA ex-
pression (e.g., cell cycle control [65] and DNA replication [24])
(Fig. 1C). However, various DNA damage response (DDR) path-
ways were also identified in addition to ubiquitin-mediated pro-
teolysis (specifically Cullin-RING ubiquitin ligases [CRLs]). A cel-
lular mechanism that regulates CRLs (66–68) and many of the
listed DDR pathways (69–71) is the ubiquitin-like modification
NEDDylation. Of note, we recently showed that blocking
NEDDylation in cells latently infected with KSHV resulted in the
activation of RTA expression but inhibited viral DNA replication
(62). Interestingly, a similar observation (with regard to effects on
viral gene expression and viral DNA replication) was recently re-
ported for the betaherpesvirus human cytomegalovirus (HCMV);
blocking of NEDDylation also led to increased immediate early
gene expression in the absence of viral DNA replication (72). Fur-
thermore, both of these reports showed that Cullin 4B was partic-
ularly important for regulating viral gene expression (62, 72).
In addition to investigating cellular pathways associated with
RTA expression, we compiled a list of the top 15 proteins that
showed increases in abundance in RTA-expressing cells (Table 1).
Interestingly, a number of proteins associated with transcriptional
repression were identified [cell division cycle-associated 7-like
(15.5-fold increase), Polycomb group protein Lethal(3)malignant
brain tumor-like protein 3 (5.7-fold increase), and lysine-specific
demethylase 2A (5.2-fold increase)]. We also note that RTA ex-
pression was associated with an increased abundance of protein
LYRIC (7.0-fold increase), which has been shown to activate
NF-B (Table 1); intriguingly, these data suggest that RTA is as-
sociated with the expression of factors that one would predict to
inhibit RTA’s transcriptional activity. In accordance with this, we
also applied ingenuity pathway analysis (IPA) to the same data set,
and the top canonical pathway identified, in addition to cell cycle
control, DNA replication, and various DNA damage pathways,
was “transcriptional repression” (Table 2). We are currently in-
vestigating some of these observations, and in this report, we focus
on the novel protein ARID3B (7.5-fold increase). There are a
number of features that led us to investigate ARID3B. Relatively
little is known about this protein, and using KSHV as a tractable
model system, we wished to further study its function. It has been
shown that ARID3B functions as a transcription factor linked with
prosurvival mechanisms during developmental processes (44–
46), and these functions may be beneficial for reactivation. Fur-
thermore, ARIDs have been described as DNA binding domains
that favor A/T-rich sequences; given the predominance of A/T-
rich elements in regulatory regions of the KSHV genome (RREs,
oriLyt etc.), we hypothesized that ARID3B would cooperate with
RTA during reactivation of the lytic cycle.
FIG 1 Analysis via SILAC coupled to LC-MS/MS of nuclear proteome
changes in response to KSHV-RTA expression. Flp-In-293 cells were used to
develop a cell line with doxycycline (Dox)-inducible FLAG-tagged RTA ex-
pression (iRTA-293). (A) Cells were labeled with R10K8 (heavy)- or R0K0
(light)-labeled SILAC medium for 2 weeks. FLAG-RTA expression was in-
duced in heavy-labeled cells for 12 h, and these were fractionated into nuclear
and cytoplasmic compartments. Fractionation success was validated by im-
munoblot analysis using the nuclear (Lamin-B1) and cytoplasmic (GAPDH)
markers. As expected, RTA expression was largely restricted to the nuclear
compartment and was found only in doxycycline-treated cells. (B) FLAG-RTA
expression was analyzed by confocal immunofluorescence that revealed that
all doxycycline-treated cells were positive for FLAG-RTA and untreated cells
(-Dox; R0K0-labeled cells) were negative for RTA expression, demonstrating
tight regulation of FLAG-RTA. Bars, 10 m. (C) KEGG pathway analysis of
nuclear proteins that were upregulated 2-fold or more due to RTA expression,
with at least 2 independent peptides revealing various cellular pathways asso-
ciated with RTA expression. GO term, gene ontology term.
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To investigate how RTA expression might lead to an increase in
ARID3B levels, we induced RTA expression in iRTA-293 cells
in addition to reactivating the lytic cycle in TREx-BCBL-1-RTA
cells (see Materials and Methods for a description of the cell
lines used in this study). We performed RT-qPCR analysis and
found that RTA, and lytic reactivation, led to a small but re-
producible increase in ARID3B mRNA expression (ca. 2.5-fold
increase [Fig. 2A]). We also reactivated the lytic cycle in iSLK-
BAC16 and TREx-BCBL-1-RTA cells and performed immuno-
blot analyses using antibodies specific for ARID3B (Fig. 2B).
This showed that lytic reactivation led to an approximately 1.5-
to 2-fold increase in ARID3B expression (Fig. 2C). These
changes are modest but likely reflect the superior sensitivity of
mass spectrometry and the semiquantitative nature of immu-
noblot data. Together, these data demonstrate that RTA, and
the KSHV lytic cycle, enhances ARID3B expression at both the
RNA and protein levels.
ARID3B is relocalized during reactivation. Given that ARID3B
expression levels were influenced by RTA expression and lytic
reactivation, we next asked whether it was involved in regulating
the KSHV lytic cycle. Using an immunofluorescence microscopy
approach, we showed that in latently infected TREx-BCBL-1-RTA
cells, ARID3B expression displayed a pan-nuclear (excluding nu-
cleolus) localization [Fig. 3A, -Dox (latent)]. However, upon lytic
reactivation, ARID3B is relocalized to discrete, RTA-positive foci,
with close proximity to the nuclear periphery [Fig. 3A, Dox
(lytic); compare the RTA-positive, reactivated cells to the RTA-
negative cell in the same field of view], reminiscent of replication
compartments (also known as replication and transcription com-
partments [RTCs]). Replication compartments are distinct, RTA-
positive foci found at the nuclear periphery associated with newly
replicated viral DNA (which is observed via incorporation of bro-
modeoxyuridine [BrdU] or EdU that specifically marks viral DNA
due to KSHV’s ability to block cellular DNA replication during
reactivation). We performed an independent experiment to ask if
ARID3B did indeed relocalize to these foci. Consequently,
ARID3B was again shown to costain with RTA and to colocalize
with EdU-positive foci (Fig. 3B), suggesting that it did indeed
relocalize from a pan-nuclear pattern into KSHV replication com-
partments upon lytic reactivation.









coverage (%) PEPb Functiona
ATPase family AAA domain-
containing protein 3B
Q5T9A4-1 53.4 12 19.8 1.90E	79 May play a role in a mitochondrial network
organization typical for stem cells
Cell division cycle-associated
7-like protein
Q96GN5-1 15.5 3 9.3 1.68E	18 Transcriptional repressor
Transmembrane protein 43 Q9BTV4 11.9 7 24.8 1.18E	55 May have a role in maintaining nuclear envelope
structure




Q9Y520-7 10.8 39 17 1.39E	164 Unknown
Centrosomal protein of 170
kDa
Q5SW79-1 9.6 19 14.3 2.53E	66 Plays a role in microtubule organization
Uncharacterized protein
KIAA1671
Q9BY89-1 9.3 4 2.6 3.61E	11 Unknown




Q8IVW6-1 7.5 8 15.7 2.25E	67 Transcription factor which may be involved in
neuroblastoma growth and malignant
transformation
General transcription factor 3C
polypeptide 2
Q8WUA4-1 7.5 3 5.5 1.88E	10 Required for RNA polymerase III-mediated
transcription
Protein LYRIC Q86UE4 7.0 4 7.7 2.99E	14 Activates the NF-B transcription factor
Cadherin-2 P19022 6.4 3 5.8 2.33E	11 Calcium-dependent cell adhesion proteins
Cytospin A Q69YQ0 6.1 3 3.3 3.88E	10 Involved in cytokinesis and spindle organization
Lethal(3)malignant brain
tumor-like 3 protein
Q96JM7-1 5.7 3 4 3.46E	07 Putative Polycomb group (PcG) protein; PcG
proteins maintain the transcriptionally
repressive state of genes
Lysine-specific demethylase 2A Q9Y2K7-1 5.2 3 2.8 8.35E	08 Histone demethylase that specifically
demethylates Lys-36 of histone H3; maintains
heterochromatin
a Protein information was annotated from the UniProt database (www.uniprot.org).
b PEP, posterior error probability (a statistical measure for peptide identification—should be below 0.1).
TABLE 2 Ingenuity pathway analysis of the top canonical pathways




Cell cycle control of chromosomal replication 7.64E	4
Mismatch repair in eukaryotes 7.84E	4
Role of BRCA1 in DNA damage response 8.12E	4
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ARID3B modulates the KSHV lytic cycle. To investigate if
ARID3B influenced the KSHV lytic cycle, we transfected iSLK-
BAC16 cells with two separate pools of ARID3B-targeted or
scramble control siRNAs and induced the lytic cycle with doxycy-
cline for 24 h. Given that ARID3B has been suggested to function
as a transcription factor, we anticipated that it might be important
for enhancing RTA-mediated expression of lytic genes. Using RT-
qPCR, we demonstrated an approximately 50% knockdown of
ARID3B. This was sufficient to enhance lytic gene expression be-
tween 1.5- and 2.5-fold, as shown for lytic genes ORF57 and gB
(Fig. 4A), suggesting that ARID3B might actually inhibit lytic gene
expression. We noticed that the two siRNAs had slightly different
effects on lytic gene expression; these two siRNA preparations
were mixtures of three different sequences, and it might be that
one of these more potently targets ARID3B. However, we cannot
fully explain this at the current time, and this difference was not
observed in other assays with this set of siRNAs. ARID3B knock-
down was also associated with an approximately 2-fold increase in
lytic protein expression (Fig. 4B and C). Accordingly, ARID3B
knockdown, followed by reactivation of the lytic cycle, also led to
a significant enhancement of KSHV genome replication com-
pared to cells transfected with a scramble control siRNA (Fig. 4D).
Importantly, knockdown in latently infected cells did not activate
viral DNA replication (Fig. 4D), suggesting that RTA expression
FIG 2 RTA enhances ARID3B expression. (A) Doxycycline-induced expres-
sion in iRTA-293 cells for 12 h and reactivation of the KSHV lytic cycle by the
addition of doxycycline in TREx-BCBL1-RTA cells increased ARID3B expres-
sion as measured by qRT-PCR. Error bars represent standard deviations from
the mean from three independent biological replicates, and quantification was
normalized to GAPDH using the CT method. Student’s t test was used to
determine statistical significance. Three independent experiments were per-
formed for each cell line. (B) Reactivation of the lytic cycle from latently in-
fected iSLK-BAC16 and TREx-BCBL1-RTA cells led to an increase in ARID3B
protein expression. In this experiment, separate immunoblots were used for
the detection of RTA (denoted by a line). Dox., doxycycline. (C) Quantifica-
tion of protein expression in panel B (see Materials and Methods). Data are
derived from two independent experiments, and error bars represent standard
deviations of the mean (calculated from technical replicates within indepen-
dent experiments). *, P 
 0.05 (Student’s t test).
FIG 3 ARID3B relocalizes to KSHV replication compartments upon reacti-
vation of the lytic cycle. (A) Confocal immunofluorescence analysis demon-
strated that ARID3B relocalized to discrete, RTA-positive foci that resemble
replication compartments (white arrows) upon doxycycline (Dox)-induced
reactivation of the KSHV lytic cycle in TREx-BCBL1-RTA cells. (B) Further
evidence suggesting that ARID3B relocalized to replication compartments,
demonstrated by its colocalization with RTA and EdU-positive foci (white
arrows). EdU is used as a marker of newly replicated virus (57). Bar, 10 m.
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or the lytic cycle was required to activate ARID3B’s inhibitory
properties.
To ask if the increases in lytic cycle-associated expression and
genome replication led to an enhanced productive infection, we
harvested and clarified medium from iSLK-BAC16 cells that had
been transfected with ARID3B siRNA and reactivated with doxy-
cycline. We transferred this medium to KSHV-negative cells
(HEK293T) and, 24 h later, purified total cellular RNA. Using
RT-qPCR analysis of the KSHV ORF57 gene as a measure of virus
infection, we demonstrated that knockdown of ARID3B led to an
enhancement of virus infection, suggesting that ARID3B knock-
down led to an increase of released virions (Fig. 4E). Together,
these data showed that ARID3B knockdown enhanced the KSHV
lytic cycle, contrary to our initial hypothesis. However, these dif-
ferences were modest given our inability to reduce ARID3B ex-
pression more than 50 to 60%. Therefore, we took an alternative
approach and asked if ARID3B overexpression could inhibit
KSHV reactivation. Here, we showed that transfection of FLAG-
tagged ARID3B, but not FLAG-SRAG (used as a control because
we know that its expression does not modulate lytic reactivation),
in iSLK-BAC16 cells for 24 h, followed by reactivation of the lytic
cycle, inhibited the expression of KSHV lytic genes (Fig. 4F). To-
gether, these data demonstrate that ARID3B is able to modulate
KSHV reactivation, and not enhance it, as originally predicted.
ARID3B interacts with an A/T-rich region of oriLyt in a lytic
reactivation-dependent manner. To investigate a potential
mechanism whereby ARID3B tempered KSHV lytic reactivation,
we tested the possibility that ARID3B interacted with RTA and
inhibited its function. RTA interacts with various cellular proteins
that are known to be inhibitory, including PARP-1 (34), TLE2
(33), and HDAC1 (35). However, coimmunoprecipitation assays
demonstrated that while RTA interacted with a known binding
partner, ORF59 (22), it did not interact with ARID3B (Fig. 5).
Next, we reasoned that ARID3B, as a DNA binding protein, might
interact with viral genomes. Furthermore, due to its predicted
preference for A/T-rich sequences, and the existence of these se-
quences in oriLyt, we focused our attention on this region of the
KSHV genome. We performed a DNA affinity assay that has pre-
viously been reported as a method for identifying proteins in-
volved in KSHV reactivation (25). Biotinylated PCR products that
spanned oriLyt were amplified from KSHV DNA (Fig. 6A), bound
to streptavidin-coated beads, and incubated with lysate from re-
activated HEK293T-rKSHV.219 cells that had been transfected
with FLAG-ARID3B 24 h earlier. Compared to control DNA (am-
plified from the RTA coding region) and a central G/C-rich repeat
region (9F), we found that ARID3B preferentially bound to region
3F, which contains the A/T-rich region of KSHV oriLyt (Fig. 6A).
ARID3B also bound to region 11F, which contained the RTA-
FIG 4 ARID3B inhibits KSHV lytic reactivation. (A) Latently infected iSLK-BAC16 cells were independently transfected with two separate siRNA pools targeting
ARID3B (or a nontargeting scramble control siRNA) for 72 h and then reactivated by addition of doxycycline (a further 24 h; see Materials and Methods).
RT-qPCR was used to quantify ARID3B, ORF57, and gB levels, and the fold difference in expression was compared to scramble control using GAPDH levels to
normalize between samples. Error bars represent standard deviations from the mean from two independent experiments, with mean values calculated from the
technical replicates of each experiment. Statistical analyses demonstrated a significant increase in lytic gene expression in ARID3B siRNA-treated cells compared
to scramble control. **, P 
 0.0001 (Student’s t test). (B) Knockdown of ARID3B led to an enhancement of lytic protein expression. (C) Quantification of panel
B (see Materials and Methods). (D) Knockdown of ARID3B enhanced viral genome replication. ARID3B siRNA or scramble control siRNA transfection of
iSLK-BAC16 cells followed by reactivation of the lytic cycle for 72 h led to an increase in viral genome replication, as quantified by qPCR of the KSHV ORF57 gene.
Cellular GAPDH was used to normalize between samples, and error bars represent standard deviations from the mean from three independent biological
replicates (*, P 
 0.05). (E) Knockdown of ARID3B enhances virion production. Media from iSLK-BAC16 cells that had been transfected with ARID3B siRNA
or scramble control siRNAs were used to infect KSHV-negative HEK293T cells. As a measure of infection, RT-qPCR analysis of the KSHV lytic gene ORF57 was
performed 24 h following infection. Data represent three independent infections in a single experiment, and Student’s t test was used to determine statistical
significance (*, P 
 0.05). (F) Overexpression of FLAG-ARID3B inhibits reactivation of lytic cycle-associated protein expression. Expression vector containing
FLAG-tagged ARID3B (FLAG-ARID3B) or FLAG-SRAG (used as a negative control) was transfected into iSLK-BAC16 cells for 24 h, followed by doxycycline
(Dox.)-induced reactivation of the KSHV lytic cycle. Cell lysates were harvested 24 h later and subjected to immunoblot analysis of lytic proteins ORF57 and mCP
(minor capsid protein).
Wood et al.
9550 jvi.asm.org October 2016 Volume 90 Number 20Journal of Virology
 on N
ovem




















responsive element (RRE), although this appeared to be slightly
reduced compared to the 3F region. Interestingly, it was shown
previously that many host and viral proteins involved in KSHV
reactivation specifically bind these two regions in oriLyt (25).
We confirmed this result using chromatin immunoprecipita-
tion (ChIP) assays using TREx-BCBL-1-RTA cells. This allowed to
us investigate whether ARID3B interacted with the KSHV genome
in infected cells, in addition to asking if this was linked with reac-
tivation of the lytic cycle. Using an antibody that has previously
been used in ChIP assays (43), we showed that endogenous
ARID3B interacted preferentially with the A/T-rich region of ori-
Lyt (3.5-fold enrichment over control IgG antibody) and not
within the RTA gene (Fig. 6B). Furthermore, we showed that this
interaction was dependent on reactivation of the KSHV lytic cycle,
as no binding (above control IgG antibody) was observed in latent
cells (Fig. 6B). These data, together with data in Fig. 2 (lytic cycle-
associated relocalization) and Fig. 4 (knockdown of ARID3B does
not induce viral DNA replication), suggest that ARID3B influ-
ences KSHV biology only upon reactivation of the lytic cycle.
DISCUSSION
It is well established that KSHV is the etiologic agent of various
malignancies in immunocompromised individuals, particularly
those infected with HIV. Indeed, KS is the most prevalent malig-
nancy in regions with endemic HIV and, for HIV sufferers, is one
of a number of diseases that are used as a guideline for the diag-
nosis of AIDS (i.e., KS is considered an AIDS-defining disease) (2).
Importantly, various reports, including data from clinical studies,
link reactivation of the KSHV lytic cycle with the pathogenesis of
KS. Therefore, it is imperative that we understand the mecha-
nisms that regulate this aspect of KSHV biology. RTA, the KSHV
lytic switch protein, is both necessary and sufficient for reactiva-
tion of the lytic cycle (8). While we have a relatively good under-
standing of how RTA drives the viral transcriptional program re-
sponsible for lytic reactivation (8), how RTA influences cellular
responses is less well understood. In this report, we developed a
cell line with inducible RTA expression and, by applying a quan-
titative proteomics approach, used it to investigate what impact
RTA expression has on the cellular proteome.
We identified a number of cellular pathways that were associ-
ated with RTA expression, and some of these are the focus of
current research. Of note, ubiquitin-mediated proteolysis was one
of the gene ontology terms included in our bioinformatics analy-
ses. We, and others, have recently reported the importance of this
pathway for regulating herpesvirus gene expression and demon-
strated that this pathway represents a potential therapeutic target
for the treatment of herpesvirus disease (62, 72). In addition to
studying cellular pathways, we generated a list of the top 15 pro-
teins based on increased protein abundance in RTA-expressing
cells. In this report, we focused on a little-known protein,
ARID3B. We initially hypothesized that, as a prosurvival tran-
scription factor (43, 44), this protein would cooperate with RTA
during reactivation of the lytic cycle. However, we actually found
that ARID3B played an inhibitory role, and its expression was
associated with modulating lytic reactivation.
A hallmark of all herpesviruses is their ability to establish a
latent infection characterized by a highly restricted gene expres-
sion program. This is an incredibly effective means of evading
detection by the immune system and ensures that infection is
maintained throughout the life of the host. Nevertheless, periodic
reactivation of the lytic cycle is necessary in order to maintain the
population of infected cells. However, the lytic cycle must be ex-
quisitely regulated so that it does not lead to uncontrolled virion
production and severe disease in its host. We observed that upon
FIG 5 RTA and ARID3B do not directly interact. Immunoprecipitation assay
showing that RTA interacts with known binding partner ORF59 but not
ARID3B. The lytic cycle was induced in ARID3B-transfected iSLK-BAC16
cells. Proteins were immunoprecipitated with the indicated antibodies, fol-
lowed by immunoblot (IB) analysis.
FIG 6 ARID3B interacts with the KSHV genome in a lytic reactivation-depen-
dent manner. (A) DNA affinity assays performed according to the method in
reference 25; biotinylated PCR products spanning oriLyt left of KSHV
(GenBank accession number NC_009333.1) and control DNA amplified from
the RTA coding region were bound to streptavidin-Dynabeads and incubated
with lysates from reactivated 293T rKSHV.219 cells expressing FLAG-
ARID3B. This suggested that ARID3B bound these sequences with preference
for the A/T-rich region. IB, immunoblotting. (B) TREx-BCBL1-RTA cells
were treated with doxycycline for 18 h (w/Dox) to reactivate the lytic cycle or
were left untreated (w/o Dox). Samples were subjected to ChIP with an anti-
body to ARID3B or normal rabbit IgG and primers specific for sequences in the
A/T-rich region of oriLyt or the RTA coding region. The percentage of output
versus input DNA was calculated and is presented relative to normal rabbit IgG
values from unreactivated (w/o Dox) cells (set to 1). Data represent two bio-
logical replicates (i.e., independent ChIPs) and two technical replicates per
ChIP from a single experiment, and values are given as the mean  standard
deviation. Student t tests were used to determine statistical significance.
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RTA expression, or reactivation of the lytic cycle, ARID3B expres-
sion was increased at both the mRNA and protein levels. To as-
certain if this had functional consequences for KSHV reactivation,
we performed a series of experiments that showed that ARID3B
was able to block reactivation. This included siRNA-mediated
knockdown of ARID3B, which resulted in enhanced lytic gene
expression and lytic protein expression and an increase in genome
replication. Furthermore, knockdown of ARID3B potentially led
to an increase in virion production, as suggested by reinfection
assays. As an alternative approach, overexpression of ARID3B sig-
nificantly abrogated lytic protein expression. Importantly, knock-
down of ARID3B in latently infected cells did not reactivate the
lytic cycle, suggesting that it was not involved in the maintenance
of latency. Therefore, RTA-mediated activation of ARID3B spe-
cifically served to regulate lytic reactivation; however, it is also
possible that this inhibitory function may be important during the
establishment phase of latency.
KSHV reactivation leads to the upregulation of several negative
feedback processes that temper the lytic cycle, many of which cen-
ter on abrogating RTA’s interaction with RBP-J (required for
transactivating various lytic gene promoters via the “indirect”
mechanism [8]). For example, and in a similar vein as the ob-
served RTA-enhanced ARID3B expression, RTA enhances the ex-
pression of the corepressor transducin-like enhancer of split 2
(TLE2), which blocked lytic reactivation by competing with
RBP-J for the same binding site in RTA (33) (we did not identify
TLE2 in our data sets). Lytic reactivation also promotes nuclear
translocation of the transcription factor NF-B, which in turn
negatively regulates lytic cycle-associated gene expression by com-
peting with RTA for RBP-J binding (32, 73, 74). Furthermore,
activated NF-B is required for the expression of latency-associ-
ated genes (e.g., LANA, vFLIP, and vCyclin), and LANA has been
shown to inhibit lytic reactivation, again, by interfering with
RTA–RBP-J interactions (75, 76). Additional negative regula-
tory mechanisms involve RTA interactions with histone deacety-
lase enzymes HDAC1 (35) and SIRT1 (77), which limits RTA’s
ability to activate lytic gene transcription. We do not currently
know how RTA led to increases in ARID3B expression. As a tran-
scription factor, RTA may drive the expression of ARID3B; it may
also be possible that RTA induces ARID3B expression indirectly.
Here, two possibilities exist: (i) RTA expression may promote a
cellular response that is linked to ARID3B expression or (ii) RTA
may sequester a repressor that would normally silence ARID3B. As
there are no reports describing the regulation of ARID3B expres-
sion, it is not possible to go beyond speculation.
Commencement of the lytic cycle leads to a dramatic remod-
eling of the cell nucleus and the formation of discrete foci (termed
replication compartments) where viral transcription, genome
replication, and capsid assembly take place (78). For KSHV, the
formation of replication compartments was recently shown to be
dependent on the chaperone function of Hsp70 proteins (57). We
observed that, upon lytic reactivation, ARID3B relocalized from a
pan-nuclear pattern to replication compartments as shown by its
colocalization with RTA and EdU. Of note, it was also recently
shown that lytic reactivation induced the relocalization of TLE2
into replication compartments (33), highlighting a common fea-
ture among negative regulators of the lytic cycle. This suggested
that ARID3B might inhibit reactivation by interacting with a pro-
tein required for lytic reactivation (cellular or viral), or the viral
genome, although these scenarios are not necessarily mutually
exclusive. Interestingly, RTA and ARID3B did not interact. This
was somewhat surprising; however, as ARID3B is a DNA binding
protein, an interaction with RTA may not be necessary for it to
associate with reactivated KSHV. Therefore, unlike the majority of
lytic cycle regulators that have been shown to interact directly with
RTA, ARID3B performs this task via a different mechanism.
We reasoned that ARID3B, as a DNA binding protein, might
interact with viral genomes. Particularly, given its proposed pref-
erence for A/T-rich sequences and the presence of these sequences
in oriLyt, we considered the possibility that ARID3B binds to this
region of the genome. Indeed, DNA affinity (Fig. 6A) and ChIP
(Fig. 6B) assays demonstrated that this was the case. The DNA
affinity assay showed us that overexpressed ARID3B preferentially
bound to a region of oriLyt that also contains A/T-rich palin-
dromic sequences in addition to a downstream region which con-
tained the RTA-responsive element (RRE). Interestingly, it was
previously shown that many host and viral proteins involved in
KSHV reactivation specifically bind these two regions in oriLyt
(25).
Importantly, ChIP assays not only allowed us to confirm bind-
ing in vivo, but they also allowed us to ask if ARID3B’s interaction
was dependent on lytic reactivation. This was an important ques-
tion as much of our data suggested that ARID3B’s inhibitory
properties were associated with RTA expression, which is silenced
during latency; for example, and as mentioned above, knockdown
of ARID3B from latently infected cells did not appear to stimulate
lytic gene expression (suggesting that it does not have a role in the
maintenance of latency). Strikingly, this interaction was indeed
dependent on reactivation of the lytic cycle, as no binding was
observed on the latent genome. This might suggest that the chro-
matinized latent KSHV genome precludes ARID3B access; how-
FIG 7 A model of how ARID3B inhibits lytic reactivation. Periodic reactiva-
tion of KSHV involves replication of the viral genome and the production of
new virions, a necessary step for the maintenance of latency and the pathogen-
esis of KS (2). Viral DNA replication initiates from the cis-acting oriLyt where
proteins essential for this process are recruited. These include viral proteins
RTA and K8 and the six core proteins (DNA polymerase, DNA processivity
factor, etc.) (80) in addition to various cellular trans-acting proteins (25). We
hypothesize that during reactivation RTA is expressed, leading to the enhanced
expression of ARID3B and its recruitment to viral genomes, specifically AT-
rich elements such as those found in oriLyt. ARID3B may compete with factors
required for reactivation for binding with the KSHV genome in order to mod-
ulate the levels of reactivation or for the establishment of latency.
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ever, upon reactivation, which is associated with removal of
nucleosomes, ARID3B can bind. However, it is not currently
known if ARID3B binding is dependent on chromatin status of
DNA. Additionally, whether this is dependent on direct DNA
binding or requires PPIs and whether ARID3B blocks transcrip-
tion or DNA replication are still open questions. Nevertheless,
these data provide weight to the hypothesis that ARID3B specifi-
cally responds to reactivation of the lytic cycle from latency and
inhibits it via interactions with the KSHV genome. We propose
that this interaction likely competes with oriLyt-associated factors
required for reactivation of the lytic cycle (Fig. 7).
We were surprised to observe that RTA expression induced a
number of proteins and pathways associated with transcriptional
silencing (Tables 1 and 2). Although it will be critical to validate
these observations, this might not be surprising given that de novo
KSHV infection of tissue culture cells leads to viral latency, despite
an initial burst of lytic cycle-associated gene expression (79).
Therefore, while RTA drives expression from the viral genome
during reactivation, it may also induce a number of processes
(directly or indirectly) that ultimately silence lytic gene expres-
sion.
In summary, we have identified a novel cellular protein,
ARID3B, which responds to the lytic cycle of KSHV and functions
to inhibit it. Lytic cycle-associated induction of negative feedback
mechanisms is clearly an important feature of herpesvirus biology
and is consistent with a virus that favors lifelong infection of its
host.
ACKNOWLEDGMENTS
We thank Karen Cowden Dahl (University of Notre Dame) and Stuart
Wilson (University of Sheffield) for providing plasmid DNA, Jae Jung
(University of Southern California) for cells, and David Blackbourn (Uni-
versity of Surrey) for RTA antisera. We also thank the Leeds University
Bioimaging Facility and Jill McVee (University of St. Andrews) for assis-
tance with confocal microscopy and Christopher Simmons-Riach (Uni-
versity of St. Andrews) for excellent technical assistance.
FUNDING INFORMATION
This work, including the efforts of Adrian Whitehouse, was funded by
Wellcome Trust (089330/z/09/z). This work, including the efforts of Da-
vid John Hughes, was funded by Wellcome Trust (ISSF). This work, in-
cluding the efforts of Adrian Whitehouse, was funded by Biotechnology
and Biological Sciences Research Council (BBSRC) (BB/K000306/1). This
work, including the efforts of Adrian Whitehouse, was funded by York-
shire Cancer Research (L366).
REFERENCES
1. Dittmer DP, Damania B. 2013. Kaposi sarcoma associated herpesvirus
pathogenesis (KSHV)—an update. Curr Opin Virol 3:238 –244. http://dx
.doi.org/10.1016/j.coviro.2013.05.012.
2. Mesri EA, Cesarman E, Boshoff C. 2010. Kaposi’s sarcoma and its asso-
ciated herpesvirus. Nat Rev Cancer 10:707–719. http://dx.doi.org/10.1038
/nrc2888.
3. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. 2005.
Inhibiting primary effusion lymphoma by lentiviral vectors encoding
short hairpin RNA. Blood 105:2510 –2518. http://dx.doi.org/10.1182
/blood-2004-08-3052.
4. Ambroziak JA, Blackbourn DJ, Herndier BG, Glogau RG, Gullett JH,
McDonald AR, Lennette ET, Levy JA. 1995. Herpes-like sequences in
HIV-infected and uninfected Kaposi’s sarcoma patients. Science 268:582–
583. http://dx.doi.org/10.1126/science.7725108.
5. Quinlivan EB, Zhang C, Stewart PW, Komoltri C, Davis MG, Wehbie
RS. 2002. Elevated virus loads of Kaposi’s sarcoma-associated human
herpesvirus 8 predict Kaposi’s sarcoma disease progression, but elevated
levels of human immunodeficiency virus type 1 do not. J Infect Dis 185:
1736 –1744. http://dx.doi.org/10.1086/340652.
6. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Nde-
mera B, Gudza I, Fitzpatrick L, Schooley RT. 2000. Relationship of
human herpesvirus 8 peripheral blood virus load and Kaposi’s sarcoma
clinical stage. AIDS 14:2109 –2116. http://dx.doi.org/10.1097/00002030
-200009290-00006.
7. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson
CA. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis
treated with a ganciclovir implant. Roche Ganciclovir Study Group. N
Engl J Med 340:1063–1070.
8. Guito J, Lukac DM. 2012. KSHV Rta promoter specification and viral
reactivation. Front Microbiol 3:30. http://dx.doi.org/10.3389/fmicb.2012
.00030.
9. Dalton-Griffin L, Wilson SJ, Kellam P. 2009. X-box binding protein 1
contributes to induction of the Kaposi’s sarcoma-associated herpesvirus
lytic cycle under hypoxic conditions. J Virol 83:7202–7209. http://dx.doi
.org/10.1128/JVI.00076-09.
10. Yu F, Feng J, Harada JN, Chanda SK, Kenney SC, Sun R. 2007. B cell
terminal differentiation factor XBP-1 induces reactivation of Kaposi’s sar-
coma-associated herpesvirus. FEBS Lett 581:3485–3488. http://dx.doi.org
/10.1016/j.febslet.2007.06.056.
11. Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL,
Tosato G, Blauvelt A, Yarchoan R. 2001. Hypoxia induces lytic replica-
tion of Kaposi sarcoma-associated herpesvirus. Blood 97:3244 –3250.
http://dx.doi.org/10.1182/blood.V97.10.3244.
12. Bu W, Carroll KD, Palmeri D, Lukac DM. 2007. Kaposi’s sarcoma-
associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch pro-
tein functions as a tetramer. J Virol 81:5788 –5806. http://dx.doi.org/10
.1128/JVI.00140-07.
13. Tsai WH, Wang PW, Lin SY, Wu IL, Ko YC, Chen YL, Li M, Lin SF.
2012. Ser-634 and Ser-636 of Kaposi’s sarcoma-associated herpesvirus
RTA are involved in transactivation and are potential Cdk9 phosphoryla-
tion sites. Front Microbiol 3:60. http://dx.doi.org/10.3389/fmicb.2012
.00060.
14. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G. 1998. A viral gene
that activates lytic cycle expression of Kaposi’s sarcoma-associated herpes-
virus. Proc Natl Acad Sci U S A 95:10866 –10871. http://dx.doi.org/10
.1073/pnas.95.18.10866.
15. Chang PJ, Shedd D, Miller G. 2005. Two subclasses of Kaposi’s sarcoma-
associated herpesvirus lytic cycle promoters distinguished by open read-
ing frame 50 mutant proteins that are deficient in binding to DNA. J Virol
79:8750 – 8763. http://dx.doi.org/10.1128/JVI.79.14.8750-8763.2005.
16. Song MJ, Brown HJ, Wu TT, Sun R. 2001. Transcription activation of
polyadenylated nuclear RNA by RTA in human herpesvirus 8/Kaposi’s
sarcoma-associated herpesvirus. J Virol 75:3129 –3140. http://dx.doi.org
/10.1128/JVI.75.7.3129-3140.2001.
17. Chang PJ, Shedd D, Gradoville L, Cho MS, Chen LW, Chang J, Miller
G. 2002. Open reading frame 50 protein of Kaposi’s sarcoma-associated
herpesvirus directly activates the viral PAN and K12 genes by binding to
related response elements. J Virol 76:3168 –3178. http://dx.doi.org/10
.1128/JVI.76.7.3168-3178.2002.
18. Zhang J, Wang J, Wood C, Xu D, Zhang L. 2005. Kaposi’s sarcoma-
associated herpesvirus/human herpesvirus 8 replication and transcription
activator regulates viral and cellular genes via interferon-stimulated re-
sponse elements. J Virol 79:5640 –5652. http://dx.doi.org/10.1128/JVI.79
.9.5640-5652.2005.
19. Liang Y, Ganem D. 2003. Lytic but not latent infection by Kaposi’s
sarcoma-associated herpesvirus requires host CSL protein, the mediator
of Notch signaling. Proc Natl Acad Sci U S A 100:8490 – 8495. http://dx
.doi.org/10.1073/pnas.1432843100.
20. Matsumura S, Fujita Y, Gomez E, Tanese N, Wilson AC. 2005. Activa-
tion of the Kaposi’s sarcoma-associated herpesvirus major latency locus
by the lytic switch protein RTA (ORF50). J Virol 79:8493– 8505. http://dx
.doi.org/10.1128/JVI.79.13.8493-8505.2005.
21. Palmeri D, Carroll KD, Gonzalez-Lopez O, Lukac DM. 2011. Kaposi’s
sarcoma-associated herpesvirus Rta tetramers make high-affinity interac-
tions with repetitive DNA elements in the Mta promoter to stimulate
DNA binding of RBP-Jk/CSL. J Virol 85:11901–11915. http://dx.doi.org
/10.1128/JVI.05479-11.
22. Rossetto CC, Susilarini NK, Pari GS. 2011. Interaction of Kaposi’s
sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on
ARID3B Inhibits the KSHV Lytic Cycle
October 2016 Volume 90 Number 20 jvi.asm.org 9553Journal of Virology
 on N
ovem




















binding with K-Rta. J Virol 85:3833–3841. http://dx.doi.org/10.1128
/JVI.02361-10.
23. Wang Y, Li H, Chan MY, Zhu FX, Lukac DM, Yuan Y. 2004. Kaposi’s
sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication:
cis-acting requirements for replication and ori-Lyt-associated RNA
transcription. J Virol 78:8615– 8629. http://dx.doi.org/10.1128/JVI.78
.16.8615-8629.2004.
24. Wang Y, Tang Q, Maul GG, Yuan Y. 2006. Kaposi’s sarcoma-associated
herpesvirus ori-Lyt-dependent DNA replication: dual role of replication
and transcription activator. J Virol 80:12171–12186. http://dx.doi.org/10
.1128/JVI.00990-06.
25. Wang Y, Li H, Tang Q, Maul GG, Yuan Y. 2008. Kaposi’s sarcoma-
associated herpesvirus ori-Lyt-dependent DNA replication: involvement
of host cellular factors. J Virol 82:2867–2882. http://dx.doi.org/10.1128
/JVI.01319-07.
26. Gunther T, Grundhoff A. 2010. The epigenetic landscape of latent Kaposi
sarcoma-associated herpesvirus genomes. PLoS Pathog 6:e1000935. http:
//dx.doi.org/10.1371/journal.ppat.1000935.
27. Gunther T, Schreiner S, Dobner T, Tessmer U, Grundhoff A. 2014.
Influence of ND10 components on epigenetic determinants of early
KSHV latency establishment. PLoS Pathog 10:e1004274. http://dx.doi.org
/10.1371/journal.ppat.1004274.
28. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, Lee S,
Buckley JD, Laird PW, Marquez VE, Jung JU. 2010. Epigenetic analysis
of KSHV latent and lytic genomes. PLoS Pathog 6:e1001013. http://dx.doi
.org/10.1371/journal.ppat.1001013.
29. Lan K, Kuppers DA, Verma SC, Robertson ES. 2004. Kaposi’s sarcoma-
associated herpesvirus-encoded latency-associated nuclear antigen inhib-
its lytic replication by targeting Rta: a potential mechanism for virus-
mediated control of latency. J Virol 78:6585– 6594. http://dx.doi.org/10
.1128/JVI.78.12.6585-6594.2004.
30. Li Q, Zhou F, Ye F, Gao SJ. 2008. Genetic disruption of KSHV major
latent nuclear antigen LANA enhances viral lytic transcriptional program.
Virology 379:234 –244. http://dx.doi.org/10.1016/j.virol.2008.06.043.
31. Bellare P, Ganem D. 2009. Regulation of KSHV lytic switch protein
expression by a virus-encoded microRNA: an evolutionary adaptation
that fine-tunes lytic reactivation. Cell Host Microbe 6:570 –575. http://dx
.doi.org/10.1016/j.chom.2009.11.008.
32. Izumiya Y, Izumiya C, Hsia D, Ellison TJ, Luciw PA, Kung HJ. 2009.
NF-kappaB serves as a cellular sensor of Kaposi’s sarcoma-associated her-
pesvirus latency and negatively regulates K-Rta by antagonizing the RBP-
Jkappa coactivator. J Virol 83:4435– 4446. http://dx.doi.org/10.1128/JVI
.01999-08.
33. He Z, Liu Y, Liang D, Wang Z, Robertson ES, Lan K. 2010. Cellular
corepressor TLE2 inhibits replication-and-transcription-activator-
mediated transactivation and lytic reactivation of Kaposi’s sarcoma-
associated herpesvirus. J Virol 84:2047–2062. http://dx.doi.org/10.1128
/JVI.01984-09.
34. Gwack Y, Nakamura H, Lee SH, Souvlis J, Yustein JT, Gygi S, Kung HJ,
Jung JU. 2003. Poly(ADP-ribose) polymerase 1 and Ste20-like kinase
hKFC act as transcriptional repressors for gamma-2 herpesvirus lytic rep-
lication. Mol Cell Biol 23:8282– 8294. http://dx.doi.org/10.1128/MCB.23
.22.8282-8294.2003.
35. Gwack Y, Byun H, Hwang S, Lim C, Choe J. 2001. CREB-binding
protein and histone deacetylase regulate the transcriptional activity of
Kaposi’s sarcoma-associated herpesvirus open reading frame 50. J Virol
75:1909 –1917. http://dx.doi.org/10.1128/JVI.75.4.1909-1917.2001.
36. Griffiths DA, Abdul-Sada H, Knight LM, Jackson BR, Richards K,
Prescott EL, Peach AH, Blair GE, Macdonald A, Whitehouse A. 2013.
Merkel cell polyomavirus small T antigen targets the NEMO adaptor pro-
tein to disrupt inflammatory signaling. J Virol 87:13853–13867. http://dx
.doi.org/10.1128/JVI.02159-13.
37. Jackson BR, Noerenberg M, Whitehouse A. 2014. A novel mechanism
inducing genome instability in Kaposi’s sarcoma-associated herpesvirus
infected cells. PLoS Pathog 10:e1004098. http://dx.doi.org/10.1371
/journal.ppat.1004098.
38. Knight LM, Stakaityte G, Wood JJ, Abdul-Sada H, Griffiths DA, Howell
GJ, Wheat R, Blair GE, Steven NM, Macdonald A, Blackbourn DJ,
Whitehouse A. 2015. Merkel cell polyomavirus small T antigen mediates
microtubule destabilization to promote cell motility and migration. J Vi-
rol 89:35– 47. http://dx.doi.org/10.1128/JVI.02317-14.
39. Munday DC, Surtees R, Emmott E, Dove BK, Digard P, Barr JN,
Whitehouse A, Matthews D, Hiscox JA. 2012. Using SILAC and
quantitative proteomics to investigate the interactions between viral
and host proteomes. Proteomics 12:666 – 672. http://dx.doi.org/10
.1002/pmic.201100488.
40. Owen CB, Hughes DJ, Baquero-Perez B, Berndt A, Schumann S,
Jackson BR, Whitehouse A. 2014. Utilising proteomic approaches to
understand oncogenic human herpesviruses (review). Mol Clin Oncol
2:891–903.
41. Herrscher RF, Kaplan MH, Lelsz DL, Das C, Scheuermann R, Tucker
PW. 1995. The immunoglobulin heavy-chain matrix-associating regions
are bound by Bright: a B cell-specific trans-activator that describes a new
DNA-binding protein family. Genes Dev 9:3067–3082. http://dx.doi.org
/10.1101/gad.9.24.3067.
42. Rhee C, Lee BK, Beck S, Anjum A, Cook KR, Popowski M, Tucker HO,
Kim J. 2014. Arid3a is essential to execution of the first cell fate decision
via direct embryonic and extraembryonic transcriptional regulation.
Genes Dev 28:2219 –2232. http://dx.doi.org/10.1101/gad.247163.114.
43. Bobbs A, Gellerman K, Hallas WM, Joseph S, Yang C, Kurkewich J,
Cowden Dahl KD. 2015. ARID3B directly regulates ovarian cancer pro-
moting genes. PLoS One 10:e0131961. http://dx.doi.org/10.1371/journal
.pone.0131961.
44. Roy L, Samyesudhas SJ, Carrasco M, Li J, Joseph S, Dahl R, Cowden
Dahl KD. 2014. ARID3B increases ovarian tumor burden and is associ-
ated with a cancer stem cell gene signature. Oncotarget 5:8355– 8366. http:
//dx.doi.org/10.18632/oncotarget.2247.
45. Casanova JC, Uribe V, Badia-Careaga C, Giovinazzo G, Torres M, Sanz-
Ezquerro JJ. 2011. Apical ectodermal ridge morphogenesis in limb develop-
ment is controlled by Arid3b-mediated regulation of cell movements. Devel-
opment 138:1195–1205. http://dx.doi.org/10.1242/dev.057570.
46. Takebe A, Era T, Okada M, Martin Jakt L, Kuroda Y, Nishikawa S.
2006. Microarray analysis of PDGFR alpha populations in ES cell differ-
entiation culture identifies genes involved in differentiation of mesoderm
and mesenchyme including ARID3b that is essential for development of
embryonic mesenchymal cells. Dev Biol 293:25–37. http://dx.doi.org/10
.1016/j.ydbio.2005.12.016.
47. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. 2012. miR-125b
targets ARID3B in breast cancer cells. Cell Struct Funct 37:27–38. http:
//dx.doi.org/10.1247/csf.11025.
48. Joseph S, Deneke VE, Cowden Dahl KD. 2012. ARID3B induces tumor
necrosis factor alpha mediated apoptosis while a novel ARID3B splice
form does not induce cell death. PLoS One 7:e42159. http://dx.doi.org/10
.1371/journal.pone.0042159.
49. Kobayashi K, Era T, Takebe A, Jakt LM, Nishikawa S. 2006. ARID3B
induces malignant transformation of mouse embryonic fibroblasts and is
strongly associated with malignant neuroblastoma. Cancer Res 66:8331–
8336. http://dx.doi.org/10.1158/0008-5472.CAN-06-0756.
50. Kobayashi K, Jakt LM, Nishikawa SI. 2013. Epigenetic regulation of the
neuroblastoma genes, Arid3b and Mycn. Oncogene 32:2640 –2648. http:
//dx.doi.org/10.1038/onc.2012.285.
51. Oguz Erdogan AS, Ozdemirler N, Oyken M, Alper M, Erson-Bensan
AE. 2014. ARID3B expression in primary breast cancers and breast can-
cer-derived cell lines. Cell Oncol (Dordr) 37:289 –296. http://dx.doi.org
/10.1007/s13402-014-0185-5.
52. Samyesudhas SJ, Roy L, Cowden Dahl KD. 2014. Differential expression
of ARID3B in normal adult tissue and carcinomas. Gene 543:174 –180.
http://dx.doi.org/10.1016/j.gene.2014.04.007.
53. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. 2003.
Global changes in Kaposi’s sarcoma-associated virus gene expression pat-
terns following expression of a tetracycline-inducible Rta transactivator. J
Virol 77:4205– 4220. http://dx.doi.org/10.1128/JVI.77.7.4205-4220.2003.
54. Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, Lee SH, Lee
HR, Myoung J, Ganem D, Oh TK, Kim JF, Gao SJ, Jung JU. 2012.
Construction and manipulation of a new Kaposi’s sarcoma-associated
herpesvirus bacterial artificial chromosome clone. J Virol 86:9708 –9720.
http://dx.doi.org/10.1128/JVI.01019-12.
55. Sturzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. 2013. Kaposi’s
sarcoma-derived cell line SLK is not of endothelial origin, but is a contam-
inant from a known renal carcinoma cell line. Int J Cancer 132:1954 –
1958. http://dx.doi.org/10.1002/ijc.27849.
56. Myoung J, Ganem D. 2011. Generation of a doxycycline-inducible KSHV
producer cell line of endothelial origin: maintenance of tight latency with
efficient reactivation upon induction. J Virol Methods 174:12–21. http:
//dx.doi.org/10.1016/j.jviromet.2011.03.012.
57. Baquero-Perez B, Whitehouse A. 2015. Hsp70 isoforms are essential for
Wood et al.
9554 jvi.asm.org October 2016 Volume 90 Number 20Journal of Virology
 on N
ovem




















the formation of Kaposi’s sarcoma-associated herpesvirus replication and
transcription compartments. PLoS Pathog 11:e1005274. http://dx.doi.org
/10.1371/journal.ppat.1005274.
58. Vieira J, O’Hearn PM. 2004. Use of the red fluorescent protein as a
marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression.
Virology 325:225–240. http://dx.doi.org/10.1016/j.virol.2004.03.049.
59. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integra-
tive analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 4:44 –57. http://dx.doi.org/10.1038/nprot.2008.211.
60. Huang DW, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R,
Lempicki RA. 2009. Extracting biological meaning from large gene lists
with DAVID. Curr Protoc Bioinformatics Chapter 13:Unit 13.11. http:
//dx.doi.org/10.1002/0471250953.bi1311s27.
61. Gould F, Harrison SM, Hewitt EW, Whitehouse A. 2009. Kaposi’s
sarcoma-associated herpesvirus RTA promotes degradation of the Hey1
repressor protein through the ubiquitin proteasome pathway. J Virol 83:
6727– 6738. http://dx.doi.org/10.1128/JVI.00351-09.
62. Hughes DJ, Wood JJ, Jackson BR, Baquero-Perez B, Whitehouse A. 2015.
NEDDylation is essential for Kaposi’s sarcoma-associated herpesvirus latency
and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog
11:e1004771. http://dx.doi.org/10.1371/journal.ppat.1004771.
63. Nelson JD, Denisenko O, Bomsztyk K. 2006. Protocol for the fast chro-
matin immunoprecipitation (ChIP) method. Nat Protoc 1:179 –185. http:
//dx.doi.org/10.1038/nprot.2006.27.
64. Nelson JD, Denisenko O, Sova P, Bomsztyk K. 2006. Fast chromatin
immunoprecipitation assay. Nucleic Acids Res 34:e2. http://dx.doi.org/10
.1093/nar/gnj004.
65. Kumar P, Wood C. 2013. Kaposi’s sarcoma-associated herpesvirus trans-
activator Rta induces cell cycle arrest in G0/G1 phase by stabilizing and
promoting nuclear localization of p27kip. J Virol 87:13226 –13238. http:
//dx.doi.org/10.1128/JVI.02540-13.
66. Hori T, Osaka F, Chiba T, Miyamoto C, Okabayashi K, Shimbara N,
Kato S, Tanaka K. 1999. Covalent modification of all members of human
cullin family proteins by NEDD8. Oncogene 18:6829 – 6834. http://dx.doi
.org/10.1038/sj.onc.1203093.
67. Bennett EJ, Rush J, Gygi SP, Harper JW. 2010. Dynamics of cullin-RING
ubiquitin ligase network revealed by systematic quantitative proteomics.
Cell 143:951–965. http://dx.doi.org/10.1016/j.cell.2010.11.017.
68. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari
S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA,
Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR,
McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei
M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S,
Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M,
Bolen JB, Langston SP. 2009. An inhibitor of NEDD8-activating en-
zyme as a new approach to treat cancer. Nature 458:732–736. http://dx
.doi.org/10.1038/nature07884.
69. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H,
Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES.
2013. Novel DNA damage checkpoints mediating cell death induced by
the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 73:225–
234. http://dx.doi.org/10.1158/0008-5472.CAN-12-1729.
70. Ma T, Chen Y, Zhang F, Yang CY, Wang S, Yu X. 2013. RNF111-
dependent neddylation activates DNA damage-induced ubiquitination.
Mol Cell 49:897–907. http://dx.doi.org/10.1016/j.molcel.2013.01.006.
71. Hannah J, Zhou P. 2009. Regulation of DNA damage response pathways
by the cullin-RING ubiquitin ligases. DNA Repair (Amst) 8:536 –543.
http://dx.doi.org/10.1016/j.dnarep.2009.01.011.
72. Le-Trilling VT, Megger DA, Katschinski B, Landsberg CD, Ruckborn
MU, Tao S, Krawczyk A, Bayer W, Drexler I, Tenbusch M, Sitek B,
Trilling M. 2016. Broad and potent antiviral activity of the NAE inhibitor
MLN4924. Sci Rep 6:19977. http://dx.doi.org/10.1038/srep19977.
73. Grossmann C, Ganem D. 2008. Effects of NFkappaB activation on KSHV
latency and lytic reactivation are complex and context-dependent. Virol-
ogy 375:94 –102. http://dx.doi.org/10.1016/j.virol.2007.12.044.
74. Lei X, Bai Z, Ye F, Xie J, Kim CG, Huang Y, Gao SJ. 2010. Regulation
of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV
microRNA. Nat Cell Biol 12:193–199. http://dx.doi.org/10.1038/ncb2019.
75. Jin Y, He Z, Liang D, Zhang Q, Zhang H, Deng Q, Robertson ES, Lan
K. 2012. Carboxyl-terminal amino acids 1052 to 1082 of the latency-
associated nuclear antigen (LANA) interact with RBP-Jkappa and are re-
sponsible for LANA-mediated RTA repression. J Virol 86:4956 – 4969.
http://dx.doi.org/10.1128/JVI.06788-11.
76. Kaul R, Verma SC, Robertson ES. 2007. Protein complexes associated
with the Kaposi’s sarcoma-associated herpesvirus-encoded LANA. Virol-
ogy 364:317–329. http://dx.doi.org/10.1016/j.virol.2007.03.010.
77. Li Q, He M, Zhou F, Ye F, Gao SJ. 2014. Activation of Kaposi’s sarcoma-
associated herpesvirus (KSHV) by inhibitors of class III histone deacety-
lases: identification of sirtuin 1 as a regulator of the KSHV life cycle. J Virol
88:6355– 6367. http://dx.doi.org/10.1128/JVI.00219-14.
78. Schmid M, Speiseder T, Dobner T, Gonzalez RA. 2014. DNA virus
replication compartments. J Virol 88:1404 –1420. http://dx.doi.org/10
.1128/JVI.02046-13.
79. Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chan-
dran B. 2004. Concurrent expression of latent and a limited number of
lytic genes with immune modulation and antiapoptotic function by
Kaposi’s sarcoma-associated herpesvirus early during infection of pri-
mary endothelial and fibroblast cells and subsequent decline of lytic
gene expression. J Virol 78:3601–3620. http://dx.doi.org/10.1128/JVI
.78.7.3601-3620.2004.
80. AuCoin DP, Colletti KS, Cei SA, Papouskova I, Tarrant M, Pari GS.
2004. Amplification of the Kaposi’s sarcoma-associated herpesvirus/
human herpesvirus 8 lytic origin of DNA replication is dependent upon a
cis-acting AT-rich region and an ORF50 response element and the trans-
acting factors ORF50 (K-Rta) and K8 (K-bZIP). Virology 318:542–555.
http://dx.doi.org/10.1016/j.virol.2003.10.016.
ARID3B Inhibits the KSHV Lytic Cycle
October 2016 Volume 90 Number 20 jvi.asm.org 9555Journal of Virology
 on N
ovem
ber 8, 2016 by U
N
IV
E
R
S
IT
Y
 O
F
 LE
E
D
S
http://jvi.asm
.org/
D
ow
nloaded from
 
